$KOD

Kodiak Sciences' tarcocimab and tabirafusp-ted showed noninferiority to aflibercept in treating wet AMD in the DAYBREAK trial. Tarcocimab improved BCVA by 7.2 letters vs 7.6 for aflibercept, while tabirafusp-ted improved BCVA by 6.3 letters. Kodiak plans to submit a BLA for tarcocimab in 2026, supported by multiple trials.

Kodiak Sciences (KOD) shares rose after presenting positive Phase 3 and Phase 1b data for its eye drugs Zenkuda and KSI-501 at the American Academy of Ophthalmology 2026 meeting. The data showed efficacy and safety in treating wet age-related macular degeneration, boosting investor confidence ahead of a potential regulatory filing. The company has no approved drugs yet and is burning cash, which poses risks.

Kodiak Sciences (KOD) stock surged over 600% in a year, closing at $94.45 on October 2, 2026. The rise was driven by successful Phase 3 trial results for Zenkuda and tabirafusp-ted, which met primary endpoints in treating wet age-related macular degeneration. The company plans to file a biologics license application in Q4 2026 but reported a net loss of $65.6 million in Q2 2026. Analysts have a Strong Buy consensus with an average price target of $116.67.

BAKER BROS. ADVISORS LP increased its stake in Kodiak Sciences Inc (KOD) by 10.69%, acquiring 2.13 million shares at $89.92 each. The firm now owns 35% of KOD, which makes up 9.88% of its portfolio. Kodiak, a clinical-stage biopharmaceutical company, has seen significant stock momentum but reports no product revenue and negative profitability metrics. The stock is currently overbought, with an RSI of 85.27.

Kodiak Sciences reported positive Phase III study results for its wet AMD treatments, Zenkuda and tabirafusp-ted, showing non-inferiority to aflibercept. Zenkuda met primary endpoints, with 54% of patients reaching a 24-week dosing interval. Tabirafusp-ted demonstrated equivalence in visual acuity. The company plans to submit a multi-indication biologics license application for Zenkuda this year and continues Phase III trials for tabirafusp-ted in DME and KSI-101 in macular edema.

Kodiak Sciences (KOD) stock surged 300% to over $100 after positive Phase 3 results for its retinal disease treatments, but has since pulled back below $90. The DAYBREAK study showed Zenkuda met primary endpoints, with plans for a 2026 regulatory submission. Investors are now taking profits, and traders are watching for stabilization.

Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.

Kodiak Sciences (NasdaqGM:KOD) reported positive Phase 3 trial results for Zenkuda and tabirafusp-ted in treating wet age-related macular degeneration, meeting primary endpoints. The company plans to submit a BLA for three indications, aiming to leverage its platform across multiple retinal diseases. Despite pre-revenue status and cash concerns, analysts project significant revenue and earnings potential by 2029, with some predicting a 638% upside.

Baker Bros. Advisors LP and related entities reported a 35% stake in Kodiak Sciences Inc., acquiring additional common stock. Felix J. Baker, a managing member, serves on the board and holds vested stock options. The investment is for long-term purposes, with potential for further purchases or disposals based on market conditions and company prospects.

BAKER BROS. ADVISORS LP purchased 715,592 indirectly-held shares of Kodiak Sciences Inc. (KOD) at an average of $88.59 ($84.24–$89.86, $63.40M total) across 22 trades over 2026-09-28 to 2026-09-29. Filed jointly with 667, L.P. (Director), Baker Bros. Advisors (GP) LLC (Director), Baker Brothers Life Sciences LP (Director), BAKER FELIX (Director) and BAKER JULIAN (Director).